0001104659-22-103309.txt : 20220927 0001104659-22-103309.hdr.sgml : 20220927 20220927161630 ACCESSION NUMBER: 0001104659-22-103309 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220927 DATE AS OF CHANGE: 20220927 EFFECTIVENESS DATE: 20220927 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akari Therapeutics Plc CENTRAL INDEX KEY: 0001541157 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981034922 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-460011 FILM NUMBER: 221271258 BUSINESS ADDRESS: STREET 1: 24 WEST 40TH STREET STREET 2: 8TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (646) 350-0702 MAIL ADDRESS: STREET 1: 24 WEST 40TH STREET STREET 2: 8TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Celsus Therapeutics Plc. DATE OF NAME CHANGE: 20130621 FORMER COMPANY: FORMER CONFORMED NAME: Morria Biopharmaceuticals PLC DATE OF NAME CHANGE: 20120201 D 1 primary_doc.xml X0708 D LIVE 0001541157 Akari Therapeutics Plc 75/76 WIMPOLE STREET LONDON X0 UNITED KINGDOM W1G 9RT +44 20 8004 0270 UNITED KINGDOM None Celsus Therapeutics Plc. Morria Biopharmaceuticals PLC Corporation true Rachelle Jacques c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Director Melissa Bradford-Klug c/o Akari Therpeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Torsten Hombeck c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Miles Nunn c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Executive Officer Ray Prudo c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director James Hill c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Stuart Ungar c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director David Byrne c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Donald Williams c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Michael Grissinger c/o Akari Therapeutics, PLC 75/76 Wimpole Street London X0 UNITED KINGDOM W1G 9RT Director Biotechnology Decline to Disclose 06b false 2022-09-14 false true true false 0 A.G.P./Alliance Global Partners 8361 None None 590 MADISON AVE 36TH FLOOR NEW YORK NY NEW YORK 10022 FL FLORIDA MA MASSACHUSETTS NV NEVADA NM NEW MEXICO NY NEW YORK TN TENNESSEE TX TEXAS VA VIRGINIA true 12835000 12835000 0 This amount includes proceeds from the sale of American Depositary Shares (ADSs) pursuant to a concurrent registered direct offering. The amount does not include proceeds from the exercise of the warrants covered by this filing. false 21 898450 0 The compensation also covers the sale of ADSs pursuant to a concurrent registered direct offering. A.G.P./Alliance Global Partners is also entitled to reimbursement of certain expenses. 0 Working capital purposes false Akari Therapeutics Plc /s/ Torsten Hombeck Torsten Hombeck Chief Financial Officer 2022-09-27